We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 01, 2020

Anti–PD-1 Treatment May Be Associated With Improved Survival in Patients With Severe Ipilimumab-Related Toxicity

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
JAMA Dermatol 2020 Jul 15;[EPub Ahead of Print], A Brunot, JJ Grob, G Jeudy, F Grange, B Guillot, N Kramkimel, L Mortier, Y Le Corre, FF Aubin, S Mansard, C Lebbé, A Blom, H Montaudie, D Giacchero, S Prey, D Legoupil, A Guyot, M Amini-Adle, F Granel-Brocard, N Meyer, M Dinulescu, J Edeline, B Campillo-Gimenez, T Lesimple

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading